Background: TMPRSS2-ERG fusions have been identified in about one-half of all prostatic adenocarcinomas (PCas). Fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction have been the most commonly used techniques in this setting. The aim of this study was to evaluate the utility of ERG immunoexpression as a surrogate for TMPRSS2-ERG fusion in a large series of PCa cases.
P rostate cancer is the most common malignancy in men with the estimate being 217,300 new cases and 32,050 deaths in the United States in 2010. 18 Claims have been made that current serum prostate-specific antigen (PSA)based screening strategies might lead to the overtreatment of a subset of patients with prostatic adenocarcinoma (PCa), 38 promoting the search for clinicopathologic and molecular profiles that may be useful for identifying patients with biologically significant tumors. In 2005, Petrovics et al 33 identified ERG, 1 of the members of the erythroblastosis virus E26 oncogene homolog (ETS) family of transcription factors, as a frequently overexpressed protooncogene in prostatic carcinomas. Shortly after, Tomlins et al 39 discovered that the mechanism for ERG overexpression entailed a recurring gene fusion involving ERG and the androgen-responsive gene TMPRSS2. In brief, they found that TMPRSS2 was fused either with ERG or ETV1 (both being the members of the ETS family) after interchromosomal or intrachromosomal rearrangements. This led to an overexpression of the ETS-related gene as a consequence of androgendependant stimulation of the resulting fusion gene. Thereupon, several studies confirmed that TMPRSS2-ETS fusions are detected in 15% to 70% of all PCa cases. 5 Recent studies have found that approximately 50% of PSA-screened PCa patients show evidence of ERG fusion. 20, 27, 40 Among all the members of the ETS family, ERG is the most frequently reported gene that is fused with TMPRSS2 and is present in >90% of all TMPRSS2-ETS gene fusion events. 5, 23 ERG and TMPRSS2 are both located on chromosome 21q, and are separated by a 3-mega base segment containing a number of other genes. The most common mechanism of TMPRSS2-ERG fusion is deletion of the intervening DNA segment, which is detected in about two-thirds of all fusion-positive cases; however, translocations are also identified. 29, 42, 45 In addition, other genes of the ETS family (including ETV1 on chromosome 7p, ETV4 on chromosome 17q, and ETV5 on chromosome 3q) have also been identified in fusion transcripts. Furthermore, ETS-related genes can also have other fusion partners besides TMPRSS2, such as SLC45A3, HERV-K17, CI5orf21, CANT-2, and HNRPA2B1, among others. 5, 23, 29 ERG (ETS-related gene-1) is a member of the ETS family of transcription factors involved in several key cellular events, such as proliferation, differentiation, stem cell development, angiogenesis, hematopoiesis, migration, oncogenic transformation, and apoptosis. 5, 23 Some studies have found an association between TMPRSS2-ERG fusions in prostate cancer and biochemical recurrence, 28, 31, 43, 46 metastases, 8, 25 or cancer-related death, 2, 8 suggesting that PCa in which these rearrangements are identified behave more aggressively. In addition, the presence of 2 or more copies of the TMPRSS2-ERG fusion product has been linked to higher pathologic stage, early biochemical recurrence, and poor survival. 2, 14, 46 However, other studies reported favorable or no significant prognostic association between TMPRSS2-ERG fusion and outcome 11, 12, 14, 21, 36, 42, 44, 45 or high-risk morphologic features. 10, 14 These inconsistent results may be related to differences in study designs, selections of end points, population heterogeneity, or technical discrepancies for the gene fusion detection methods.
Detection of TMPRSS2-ERG fusions is most commonly carried out using either fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction, but these methods are costly and require considerable infrastructure and expertise. Recently, using a commercial rabbit monoclonal antibody in 207 cases of PCa, Park et al 30 found a strong association between ERG protein expression and ERG gene rearrangement status defined by FISH. Classifier performances and receiver-operating characteristic (ROC) curve analyses pointed to a high sensitivity, specificity, and accuracy for ERG immunohistochemistry in defining the TMPRSS2-ERG fusion status in this series. In addition, using a different mouse monoclonal antibody, Furusato et al 13 found evidence of ERG expression in 45% of 132 PCa cases studied using whole-mounted sections. They also analyzed 10 specimens from their series by FISH and found no discrepancies between ERG expression and TMPRSS2-ERG fusion status. Both studies showed excellent concordance between the ability to detect ERG protein in nuclei of prostate tumor cells and the presence of genomic alterations of ERG as detected by FISH or reverse transcription polymerase chain reaction. This thereby suggests that identification of ERG could have clinical applications, eg, improving the accuracy of prostate cancer diagnosis on needle biopsies. The aim of this study was to assess ERG protein staining as a surrogate for FISH, by attempting to validate and extend these studies using a larger well-defined cohort of prostate cancer patients that were recently characterized for TMPRSS2-ERG rearrangements. 41 
MATERIALS AND METHODS

Tissue Microarray Construction
The currently analyzed cases are part of a nested case-control study on recurrence that included 4860 men who underwent radical retropubic prostatectomy (RRP) for clinically localized PCa at The Johns Hopkins Medical Institutions (Baltimore, MD) between 1993 and 2004. Patients did not receive hormonal or radiation therapy before RRP or adjuvant therapy before recurrence. Five hundred twenty-four men from this cohort experienced biochemical recurrence (serum PSA >0.2 ng/ mL), metastasis, or died of PCa after surgery. For each 1 of these cases, incidence density sampling was used to select a control who had not experienced recurrence by the date of the case's recurrence and who was matched on age, race, pathologic stage, and Gleason sum. A set of 16 tissue microarrays (TMAs) was constructed for the 524 matched cases and controls. Matched pairs were placed on the same TMA, so that a subset of the TMAs could be used depending on sample size calculations. Paired PCa and noncancer tissues were spotted (0.6 mm) in triplicate from each RRP specimen as previously described by Kononen et al. 19 In RRP specimens with multifocal tumors, only the dominant tumor (with the highest Gleason score and usually largest) was sampled. The first 10 of the 16 available TMAs, corresponding to 427 RRP, were used for this study based on power calculations for the previous FISH study. 41 Consecutive sections of the same TMA were used for FISH analysis and for ERG immunohistochemistry.
Evaluation of TMPRSS2-ERG Fusion Status by FISH
FISH analysis was conducted previously for these samples 41 using dual-color interphase break-apart probes for the 5 0 and 3 0 regions of the ERG gene, as previously described. 1, 22 In brief, 4-mm paraffin-embedded TMA sections were baked at 561C for 2 hours; then these were deparaffinized and rehydrated using xylene and graded ethanol, respectively. TMA sections were pretreated using Paraffin Pretreatment Reagent Kit III (Abbott Molecular Inc, IL). BAC FISH probes used were SpectrumGreen d-UTP direct labeled BAC RP11-95I21 for 5 0 ERG, and SpectrumOrange d-UTP direct labeled BAC RP11-476D17 for 3 0 ERG (Nick transKit, Vysis, Abbott Park, IL). TMAs and BAC FISH probes were codenatured at 941C for 5 minutes and hybridized overnight at 371C in a humid chamber (StatSpin ThermoBrite, IRIS Inc, MA). FISH interpretation was performed by 3 urologic pathologists (A.T., R.A., and G.J.N.). Digitally scanned adjacent hematoxylin and eosin sections were available for side-by-side comparison with the FISH image to localize tumor cells. Paired benign prostatic epithelium was also evaluated as a negative control. Nuclei in each TMA spot were classified in 1 of the following categories: (1) negative for TMPRSS2-ERG fusion: nucleus with 2 pairs of juxtaposed red (R) and green (G) signals forming yellow (Y) signals indicating absence of ERG fusion (2Y); (2) ERG signal split (Esplit): nucleus with 1 juxtaposed red-green signal pair of the nonrearranged ERG allele and additional separate single red and single green signals of rearranged ERG allele (break-apart) reflecting a TMPRSS2-ERG fusion through translocation (1Y1R1G); (3) ERG signal deletion (Edel): nucleus with 1 juxtaposed red-green signal pair for the nonrearranged allele and a single red signal of a rearranged allele indicating deletion of the 5 0 ERG probe region (1Y1R); (4) Duplicated ERG signal split (2Esplit): nucleus with 1 juxtaposed red-green signal pair of the nonrearranged ERG allele and 2 additional separate red and green signals of rearranged ERG allele (1Y2R2G); (5) Duplicated ERG signal deletion (2Edel): nucleus with 1 juxtaposed redgreen signal pair for the nonrearranged allele and 2 red signals of the ERG rearranged allele (1Y2R); and (6) Other types of fusion: including Esplit with gene copy number gain (CNG) (2Y1R1G), Edel with CNG (2Y1R) and Esplit/Edel with gene copy number loss (1R1G/1R). In any given TMA spot, a TMPRSS2-ERG fusion was considered to be present when a minimum of 10% of the counted nuclei contained a split or a minimum of 20% of the nuclei contained a deletion. Each case was classified in 1 or more categories taking into account the type of fusion identified by FISH at each TMA spot.
Evaluation of ERG Expression by Immunohistochemistry
ERG expression was evaluated using a commercial rabbit anti-ERG monoclonal antibody (clone EPR3864; Epitomics, Burlingame CA); this novel antibody has been recently validated. 30 The protocol for immunohistochemistry was as follows: deparaffinization and hydration of TMA slides; blocking with preantibody solution (10 min); applying anti-ERG primary antibody (1:75 for 45 min at room temperature); applying Poly-HRP anti-rabbit IgG (30 min); applying 3,3'-diaminobenzidine (20 min, Sigma Fast 3,3'-diaminobenzidine tablets, Sigma-Aldrich, St. Louis, MO); counterstaining with Mayer hematoxylin (1:5 for 1 min, Dako, Carpinteria, CA); and dehydration, clearing, mounting, and covering.
Each TMA spot was independently assessed by 2 pathologists (A.C. and G.J.N.) using an H-score system obtained by multiplying the intensity of the stain (0: no staining; 1: weak staining; 2: moderate staining; 3: intense staining) by the percentage (0 to 100) of the cell showing that staining intensity (H-score range, 0 to 300). Only nuclear staining in epithelial prostatic cells was evaluated, either in tumoral or benign tissues. As ERG expression is normally observed in lymphocytes and endothelium, 13, 30 these cells were used as internal positive controls for ERG staining, but were not included in the evaluation of ERG fusion status. Any nuclear staining positivity (H-score >0) was considered as indicative of ERG expression.
Statistical Analyses
H-scores were compared between cases with and without evidence of TMPRSS2-ERG fusion using the Mann-Whitney U test. H-scores were compared among the TMPRSS2-ERG fusion categories using the Kruskal-Wallis test, with the Dunn multiple test for post hoc pairwise comparisons. The association between the presence of TMPRSS2-ERG fusion and ERG expression was evaluated using Fisher exact test. Using the presence of any TMPRSS2-ERG fusion detected by FISH as the gold standard, sensitivity and specificity, with their respective 95% confidence intervals (95% CI), were calculated for ERG immunoexpression. ROC curves were generated as follows: using (x) 1-specificity versus (y) sensitivity charts, H-scores were plotted defining the presence of any fusion event as the state variable. The area under the curve, with its respective 95% CI, was interpreted following the criteria established by Collinson. 7 In all cases, a 2-tailed P value <0.05 was required for statistical significance. Data were analyzed using PASW Statistics version 18.0 (IBM Corporation, Somers, NY).
RESULTS
TMPRSS2-ERG fusions were detected by FISH in 195 (45.7%) of the PCa cases. The most common mechanism was Edel (158 cases), followed by Esplit (108 cases), 2Edel (24 cases), and 2Esplit (6 cases); only 4 cases with fusions not involving any of the aforementioned mechanisms were found. TMPRSS2-ERG fusions were not detected in any of the nontumoral glands, lymphocytes, or endothelial cells. ERG immunoexpression was found in 192 (45.0%) of the PCa cases and in none of the nontumoral tissue samples. Lymphocytes and endothelial cells were consistently ERG positive. Patterns of ERG immunoexpression are depicted in Figure 1 . In 64.6% of all positive cases, 90% or more of the tumor cells stained positively; in 81% of these positive cases, at least 50% of the cells were positive. Focal (5% or less) positivity was observed in only 8.6% of the positive cases. Mean H-scores were significantly higher in tumors harboring any type of TMPRSS2-ERG fusions when compared with tumors with no identifiable chromosomal rearrangements ( Table 1 ). In ERG-positive cases, the H-score ranged from 5 to 290 (mean, 143.1 ± 69; median, 164; interquartile range, 103). Although a tendency for higher H-score means in 2Esplit and 2Edel cases was observed, no differences were found among the H-scores regarding the mechanism of fusion, either as a group (P = 0.27) or by comparing each mechanism against the others (P>0.05). The association between ERG immunoexpression and the presence of TMPRSS2-ERG fusion as defined by FISH was statistically significant ( Table 2) . With regard to classifier performances, immunohistochemistry for ERG expression had a sensitivity of 86% (95% CI, 80%-90%) and a specificity of 89% (95% CI, 84%-93%) in detecting any TMPRSS2-ERG fusions. ROC curve analysis showed that ERG expression H-scores measured by immunohistochemistry had a high accuracy in identifying TMPRSS2-ERG fusions detected by FISH, with an area under the ROC curve of 0.87 (95% CI, 0.84%-0.91%; P<0.00001, Fig. 2 ).
DISCUSSION
In this study, we used a large series of cases to evaluate the ERG immunoexpression rate in PCa. We confirmed a strong association between the immunohistochemical expression of ERG in epithelial cells with prostate cancer and the presence of TMPRSS2-ERG fusions detected by FISH. These results support the contention that standard immunohistochemistry can validly be used for defining the TMPRSS2-ERG status in PCa. As mentioned above, 2 recently published studies Immunohistochemistry for ERG Expression have explored the ERG immunoexpression status in PCa patients 13, 30 ; our series confirms and expands those previous results. Strengths of our study include the large number of tissue samples and the classifier performance analysis of ERG immunoexpression factoring the various mechanisms of TMPRSS2-ERG fusion. In our study, ERG immunoexpression was not observed in any of the paired tissue samples containing benign glands or in the benign glands found next to malignant glands, when present. 30 Nevertheless, Furusato et al 13 found some rare ERG-positive benign glands, in agreement with previous studies reporting the presence of TMPRSS2-ERG fusion transcripts in isolated benign prostatic glands. 3, 6 As these foci were found in topographical relationship with areas of PCa and/or prostatic intraepithelial neoplasia (PIN), this unexpected finding might be explained by the presence of premalignant molecular alterations in those morphologically benign glands.
In a recently published study by Scheble et al, 37 more than 50 different tumor types in nearly 3000 tissue samples were evaluated for TMPRSS2-ERG fusion by FISH. The researchers did not find ERG fusions in any of the analyzed tumors, suggesting that TMPRSS2-ERG rearrangements, especially those involving deletion of the DNA segment between both genes, are PCa-specific genomic alterations. These results, along with the ones found in the present and previous studies, 13, 30 suggest that ERG immunoexpression could be used as a tissuelineage specific marker for prostatic tumors. Several studies have detected matched TMPRSS2-ERG status between PCa tumor cells and high-grade PIN present in the same specimen 4, 13, 16, 26, 30, 32 indicating that ERG fusions appear early in the development of the disease. This results suggest that ERG immunoexpression can be utilized for differentiating preneoplastic lesions from benign prostatic glands or even predict the likelihood of finding cancer in subsequent biopsies. 26 In the study by Furusato et al, 13 almost all PIN and none of the prostatic glands with adenosis (atypical adenomatous hyperplasia), sclerosing adenosis, basal cell hyperplasia, or partial atrophy were positive for ERG. This is a suggestion of the role that ERG immunoexpression might have for the differential diagnosis of atypical prostatic glands. Nevertheless, additional studies addressing this potential role are needed before such application can be considered for standard clinical use.
Our study found that immunohistochemistry for ERG overexpression had high sensitivity and specificity for detecting TMPRSS2-ERG fusions. Nevertheless, 11% to 14% of cases were "misclassified" as either false positives or false negatives. ERG immunohistochemical expression in the context of no detectable TMPRSS2-ERG fusions could be explained by the presence of fusion of ERG with other genes (such as SLC45A3, NDRG1, and FKBPS), as has been recently described. 9, 15, 30, 34, 35 In our series, CNGs were found in only 1 of the 25 cases with ERG expression and no TMPRSS2-ERG fusions, with no identifiable chromosomal rearrangements in the remaining 24 tumors. In contrast, we observed a tendency for higher H-score means in cases with 2Esplit and 2Edel cases, suggesting some CNG effect on the level of ERG expression. Although more studies are required to properly address this issue, the lack of significance of this tendency could be related to the small number of cases in the 2Esplit and 2Edel groups. In terms of false negatives, gene rearrangements coding for transcript products that cannot be detected by anti-ERG clone EPR3864 could explain TMPRSS2-ERG FISH-positive cases without ERG expression; nevertheless, this is unlikely considering that this antibody recognizes an epitope that is retained in all known ERG gene fusion isoforms. 30 Another plausible explanation for this event is decrease transcript/protein expression in tumors with TMPRSS2-ERG fusions due to alterations in androgen response signaling or posttranscriptional mechanisms. 17, 30 A third explanation of falsenegative cases could be related to topographical variations in the levels of ERG immunoexpression within the same tumor, with areas showing intense positivity while others being completely negative, a scenario sometimes found, especially when using whole-mounted sections. 13 Probably, these topographical variations in ERG expression are related to the previously reported ERG rearrangement heterogeneity found in discrete tumor nodules within the same prostate gland. 3, 24 Finally, in both previously mentioned situations (ERG overexpression with no TMPRSS2-ERG fusions and TMPRSS2-ERG fusions without ERG overexpression), misclassification due to technical factors, such as poor tissue preservation, could not be ruled out with certainty. Nevertheless, there are several advantages in using immunohistochemistry for defining the ERG status: it is less expensive, less technically challenging, and less time consuming when compared to FISH. It can detect the majority of ERG fusions, whether or not ERG is fused to TMPRSS2 or other genes, such as SLC45A3, NDRG1, or FKBPS, 9, 15, 30, 34, 35 and the criterion for ERG overexpression is straightforward (any positive tumor cell staining, ie, H-score >0). Considering that the use of TMAs in this study simulates the amount of tissue available for examination using needle biopsies, our results should be extendable to routine practice.
In summary, we found a strong association between ERG immunohistochemical overexpression and TMPRSS2-ERG fusion detected by FISH. Our results suggest that standard immunohistochemistry has high accuracy for defining the ERG fusion status in men with prostate cancer. Taking this into account, immunohistochemistry for ERG immunoexpression may offer an accurate, simpler, and less costly alternative for evaluation of ERG fusion status in PCa.
